Iranian Red Crescent Medical Journal

Published by: Kowsar

MS14, a Marine Herbal Medicine, an Immunosuppressive Drug in Experimental Autoimmune Encephalomyelitis

Abbas Ebrahimi Kalan 1 , 2 , Jafar Soleimani Rad 1 , Laya Kafami 2 , 3 , Daryoush Mohamadnezhad 1 , Amir Afshin Khaki 1 and Amaneh Mohammadi Roushandeh 1 , 4 , *
Authors Information
1 Anatomical Sciences Department, School of Medicine, Tabriz University of Medical Sciences, Tabriz, IR Iran
2 Shefa Neuroscience Research Center, Tehran, IR Iran
3 Pathobiology Department, School of Medicine, Alborz University of Medical Sciences, Karaj, IR Iran
4 Anatomical Sciences Department, School of Medicine, Hamedan University of Medical Sciences, Hamedan, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: July 5, 2014, 16 (7); e16956
  • Published Online: July 5, 2014
  • Article Type: Research Article
  • Received: December 16, 2013
  • Revised: February 2, 2014
  • Accepted: February 22, 2014
  • DOI: 10.5812/ircmj.16956

To Cite: Ebrahimi Kalan A, Soleimani Rad J, Kafami L, Mohamadnezhad D, Khaki A A, et al. MS14, a Marine Herbal Medicine, an Immunosuppressive Drug in Experimental Autoimmune Encephalomyelitis, Iran Red Crescent Med J. 2014 ; 16(7):e16956. doi: 10.5812/ircmj.16956.

Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Chen YC, Yang X, Miao L, Liu ZG, Li W, Zhao ZX, et al. Serum level of interleukin-6 in Chinese patients with multiple sclerosis. J Neuroimmunol. 2012; 249(1-2): 109-11[DOI][PubMed]
  • 2. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006; 60(1): 12-21[DOI][PubMed]
  • 3. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol. 2002; 15(3): 227-31[PubMed]
  • 4. Zozulya AL, Wiendl H. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Hum Immunol. 2008; 69(11): 797-804[DOI][PubMed]
  • 5. Rodgers JM, Miller SD. Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med. 2012; 85(4): 447-68[PubMed]
  • 6. Kafami L, Etesami I, Felfeli M, Enayati N, Ghiaghi R, Aminian A, et al. Methadone diminishes neuroinflammation and disease severity in EAE through modulating T cell function. J Neuroimmunol. 2013; 255(1-2): 39-44[DOI][PubMed]
  • 7. Nessler S, Bruck W. Advances in multiple sclerosis research in 2009. J Neurol. 2010; 257(9): 1590-3[DOI][PubMed]
  • 8. Wei W, Du C, Lv J, Zhao G, Li Z, Wu Z, et al. Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. J Immunol. 2013; 190(1): 138-46[DOI][PubMed]
  • 9. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986; 324(6092): 73-6[DOI][PubMed]
  • 10. Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer. 2000; 88(9): 2061-71[PubMed]
  • 11. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol. 1994; 9(5): 462-7[PubMed]
  • 12. Kitajima T, Tajima Y, Kuroki T, Tsuneoka N, Adachi T, Kanematsu T. Interleukin-6 expression on the biliary epithelia during inflammation-associated biliary carcinogenesis in bilioenterostomized hamsters. J Surg Res. 2010; 162(1): 54-8[DOI][PubMed]
  • 13. Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol. 1999; 100(1-2): 124-39[PubMed]
  • 14. Schonrock LM, Gawlowski G, Bruck W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett. 2000; 294(1): 45-8[PubMed]
  • 15. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol. 2004; 251(3): 261-8[DOI][PubMed]
  • 16. Roya Y, Nayere A, Naseri M. The Effect of MS14 on Production of Pro-inflammatory Cytokines by Macrophages. Iran J Basic Med Sci. 2011; 14(1): 89-93
  • 17. Naseri M, Ahmadi A, Gharahgouzli K, Nabavi M , Faghihzadeh S , Ashtarian N . Clinical and toxicological evaluation of MS14 natural product in patients with multiple sclerosis. Daneshvar Med. 2007; 14(68): 64-59
  • 18. Ahmadi A, Habibi G, Farrokhnia M. MS14, an Iranian herbal-marine compound for the treatment of multiple sclerosis. Chin J Integr Med. 2010; 16(3): 270-1[DOI][PubMed]
  • 19. Tafreshi AP, Ahmadi A, Ghaffarpur M, Mostafavi H, Rezaeizadeh H, Minaie B, et al. An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis. Phytother Res. 2008; 22(8): 1083-6[DOI][PubMed]
  • 20. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol. 2007; 4(1): 50-7[PubMed]
  • 21. Furrie E, Macfarlane S, Thomson G, Macfarlane GT, Gut Biology G, et al. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology. 2005; 115(4): 565-74[DOI][PubMed]
  • 22. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc. 2006; 1(4): 1810-9[DOI][PubMed]
  • 23. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest. 2002; 110(4): 493-7[DOI][PubMed]
  • 24. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012; 8(9): 1254-66[DOI][PubMed]
  • 25. Uzawa A, Mori M, Kuwabara S. Neuromyelitis optica: concept, immunology and treatment. J Clin Neurosci. 2014; 21(1): 12-21[DOI][PubMed]
  • 26. Leech MD, Barr TA, Turner DG, Brown S, O'Connor RA, Gray D, et al. Cutting edge: IL-6-dependent autoimmune disease: dendritic cells as a sufficient, but transient, source. J Immunol. 2013; 190(3): 881-5[DOI][PubMed]
  • 27. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007; 8(9): 967-74[DOI][PubMed]
  • 28. Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther. 2009; 13(4): 225-44[DOI][PubMed]
  • 29. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004; 173(9): 5794-800[PubMed]
  • 30. Yaraee R, Ghazanfari T, Eghtedardoost M, Rajabi M, Naseri M. The effect of MS14 on innate and cellular immune responses in BALB/c mice. Immunopharmacol Immunotoxicol. 2011; 33(3): 509-14[DOI][PubMed]
  • 31. Etemadifar M, Sayahi F, Abtahi SH, Shemshaki H, Dorooshi GA, Goodarzi M, et al. Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study. Int J Neurosci. 2013; 123(7): 480-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments